«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

20卷

期数:

2014年05期

页码:

366-369

栏目:

临床医学

出版日期:

2014-09-20

文章信息/Info

Title:

Changes of circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin  plus docetaxel

文章编号:

1006-8147(2014)05-0366-04

作者:

 闫庆贺¹; 宋世辉¹; 彭 民²; 张 鹏¹ ; 赵 娜³

(天津医科大学总医院 1.心胸外科;2.重症医学科；3.普外科研究所，天津 300052)

Author(s):

 YAN Qing-he¹; SONG Shi-hui¹; PENG Min²; ZHANG Peng¹; 　ZHAO　Na^３

(1．Department of Cardiothoracic Surgery; 2．Department of Critical Care Medicine；３．Research Institute of General Hospital,General Hospital,Tianjin Medical University,Tianjin 300052,China)

关键词:

循环内皮细胞; 非小细胞肺癌 ; 化疗

Keywords:

circulating endothelial cell; non-small cell lung cancer ; chemotherapy

分类号:

R734.2

DOI:

-

文献标志码:

A

摘要:

 目的:探索用卡铂联合多西他赛作为一线方案治疗晚期非小细胞肺癌(NSCLC),静脉血中循环内皮细胞(CECs)数目在预测化疗有效性中的作用。方法:采用卡铂联合多西他赛治疗晚期NSCLC病人53例，用流式细胞术测定NSCLC病人外周静脉血中CECs数目，同样方法测定健康人静脉血中CECs数目。结果:NSCLC病人化疗前的外周静脉血中CECs数目[(1798±970)个/mL]明显高于健康人[(135±150)个/mL]。将化疗前CECs数目视为基线值，IV期病人的基线CECs数目高于IIIB病人(P=0.036)。基线CECs数目和肿瘤体积呈明显正相关性(rs=0.556,P<0.001)。化疗后病人CECs数目明显下降[化疗第22天为(704±603)个/mL]，其中临床获益病人CECs数目下降较明显，病情进展(PD)病人CECs数目无明显下降。临床获益病人基线CECs数目明显高于PD病人(P=0.011)。结论:CECs数目可用来预测卡铂联合多西他赛治疗晚期NSCLC的有效性。

Abstract:

 Objective: To investigate the role of circulating endothelial cells (CECs) as a marker to predict the effect of a carboplatin and docetaxel based ?rst line chemotherapy in advanced non-small cell lung cancer (NSCLC). Methods： Fifty-three NSCLC patients were treated with carboplatin combined with docetaxel. Levels of CECs were measured by flow cytometry. Results：The CECs count before chemotherapy (baseline value) was signi?cantly higher in NSCLC patients than in healthy volunteers[(1798±970)/mL and (135±150)/mL, respectively]. The baseline CECs values of patients with stage IV NSCLC were signi?cantly higher than those in patients with stage IIIB NSCLC(P=0.036).The correlation between the baseline CECs count and tumor volume was positive (rs=0.556, P<0.001). CECs were decreased by chemotherapy as compared to baseline values [(704±603)/mL， d22]. The decrease was more significant in patients with clinical bene?t while the PD group patients didn’t show this change. CECs values of clinical bene?t group was signi?cantly higher than PD group (P=0.011). Conclusion：As a marker, CECs can be useful in predicting the clinical effect of the carboplatin combined with paclitaxel regimen on patients with advanced NSCLC.

参考文献/References:

[1]Folkman J. Anti-angiogenesis:new concept for therapy of solid tumors[J]. Ann Surg, 1972,175(3):409
[2]Mancuso P, Antoniotti P, Quarna J, et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses[J]. Clin Cancer Res, 2009,15(1):267
[3]Fleitas T, Martínez-Sales V, Gómez-Codina J, et al. Circulating endothelial and endothelial progenitor cells in non-small-cell lung Cancer[J]. Clin Transl Oncol, 2010,12(8):521
[4]Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelial-cell kinetics and viability predict survival in breast Cancer patients receiving metronomic chemotherapy[J]. Blood, 2006,108(2):452
[5]Laskin J J, Sandler A B. First-line treatment for advanced non-small cell lung Cancer[J]. Oncology (Williston Park), 2005,19(13):1671
[6]Baggstrom M Q, Stinchcombe T E, Fried D B, et al. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung Cancer: a meta-analysis[J]. J Thorac Oncol, 2007,2(9):845
[7]Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel,cisplatin plus gemcitabine,and cisplatin plus vinorelbine for advanced non-small-cell lung Cancer:Four-Arm Cooperative Study in Japan[J]. Ann Oncol, 2007,18(2):317
[8]Wang J, Lou P, Lesniewski R, et al. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly[J]. Anticancer Drugs, 2003,14(1):13
[9]Vacca A, Ribatti D, Iurlaro M, et al. Docetaxel versus paclitaxel for antiangiogenesis[J]. J Hematother Stem Cell Res, 2002,11(1):103
[10]Mancuso P, Calleri A, Cassi C, et al. Circulating endothelial cells as a novel marker of angiogenesis[J]. Adv Exp Med Biol, 2003,522:83
[11]Kawaishi M, Fujiwara Y, Fukui T, et al. Circulating endothelial cells in non-small cell lung Cancer patients treated with carboplatin and paclitaxel[J]. J Thorac Oncol, 2009,4(2):208
[12]Rademaker-Lakhai J M, Beerepoot L V, Mehra N, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced Cancer[J]. Clin Cancer Res, 2007,13(15 Pt 1):4474
[13]Mcauliffe J C, Trent J C. Biomarkers in gastrointestinal stromal tumor:should we equate blood-based pharmacodynamics with tumor biology and clinical outcomes?[J]. Clin Cancer Res, 2007,13(9):2643
[14]Rowand J L, Martin G, Doyle G V, et al. Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas[J]. Cytometry A, 2007,71A(2):105
[15]黄纯，李凯. 重组人血管内皮抑素联合NP方案治疗晚期非小细胞肺癌的临床观察[J]. 中华肿瘤防治杂志, 2008,15(4):283
[16]Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal Cancer[J]. N Engl J Med, 2004,350(23):2335
[17]Sandler A, Gray R, Perry M C, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung Cancer[J]. N Engl J Med, 2006,355(24):2542
[18]Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice[J]. J Clin Invest, 2000,105(8):1045
[19]吴宏菊，辛彦. 节律化疗抗血管生成效应的研究进展[J]. 中华肿瘤防治杂志, 2011,18(6):473

相似文献/References:

备注/Memo

备注/Memo:

 作者简介 闫庆贺(1987-），男，硕士在读，研究方向：心胸外科;

通信作者：宋世辉，E-mail：tjsongshihui@126.com。

常用功能

更新日期/Last Update: 2014-09-25